The integration of miRNA panels with conventional biomarkers such as BNP and NT-proBNP significantly increases diagnostic precision and improves risk stratification in HF, especially in cases with unclear clinical presentation or overlapping symptoms [39]. This evidence concerns the gene NPPB and hydrops fetalis.